RxDoctor Payments Data

Stella Baez Corujo, MD

Pulmonary Disease · Trujillo Alto, PRNPI 1073897567

Payments from drug & device makers

$851in general payments, 2019–2025

Across 44 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$369
  • GSK$199
  • AstraZeneca$79
  • Sanofi$49
  • Johnson & Johnson$47
  • Pfizer Pharmaceuticals LLC$35
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim21$369
GSK8$199
AstraZeneca4$79
Sanofi2$49
Johnson & Johnson2$47
Pfizer Pharmaceuticals LLC2$35
Mylan Specialty L.p.2$27
Mylan LLC2$26
PBG Puerto Rico LLC1$20

How this compares

$851 in reported general payments places this provider in the 20th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,283
Medicare patients
14
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter216$144,192
Stiolto RespimatTiotropium Br/Olodaterol Hcl267$130,895
NucalaMepolizumab21$76,688
Arnuity ElliptaFluticasone Furoate297$75,349
Breo ElliptaFluticasone/Vilanterol142$58,422
Spiriva RespimatTiotropium Bromide104$55,440
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$37,975
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate81$22,137
Fluticasone-SalmeterolFluticasone Propion/Salmeterol179$21,367
Albuterol Sulfate HfaAlbuterol Sulfate433$19,669
SymbicortBudesonide/Formoterol Fumarate73$18,184
Atrovent HfaIpratropium Bromide37$17,701
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,578
Fluticasone Propionate HfaFluticasone Propionate48$16,246
Wixela InhubFluticasone Propion/Salmeterol56$8,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Arnuity Ellipta, Breo Ellipta, Anoro Ellipta$199$392,626755 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$369$186,335371 claims
AstraZenecaSymbicort, Breztri Aerosphere$79$35,762100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Trujillo Alto

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →